Sector News

Resverlogix gets a $116M China drug development deal, stokes buyout buzz

April 29, 2015
Life sciences
Resverlogix has struck a deal to trade development rights in China for its lead cardio drug in exchange for a $41.5 million equity stake in the biotech along with up to $75 million in sales milestones. And today the Canadian biotech’s CEO added a sweetener, telling Bloomberg that he’s in talks with unnamed suitors to sell the company.
 
In what is becoming an increasingly familiar framework for a biotech deal, Shenzhen Hepalink Pharmaceutical acquired rights to develop RVX-208 for China, Hong Kong, Taiwan and Macau. Hepalink, which is based in the Shenzhen High-Tech Park, is paying $29 million for 12.7% of the company while Eastern Capital is adding $12.5 million, boosting its stake in Resverlogix to 24%. Resverlogix’s statement concludes that if you add in a potential royalty stream, the company stands to earn more than $332 million in future revenue off the deal, if everything works as planned.  
 
The company’s shares surged a modest 6% today as news of the claimed sales talks spread.
 
“We are in discussions with multiple companies, not just one,” CEO Donald McCaffrey told Bloomberg, tossing his hat into a crowded ring of M&A speculation. Buyout deals have become all the rage in the industry, and a steady stream of prospective M&A deals and rumors has kept analysts buzzing.
 
Resverlogix has almost all of its eggs in the RVX-208 basket, aiming at a new treatment for atherosclerosis. It’s a small molecule that inhibits BET bromodomains by boosting levels of the ApoA-I protein, which in turn make high-density lipoprotein particles that can flush plaque.
 
Last summer the small biotech touted evidence of a reduction in major cardiovascular events among diabetes patients in two studies. That news came a year after Resverlogix’s Phase IIb trial for the drug ended in failure, wiping out most of its share value and forcing the company to go into survival mode.
 
By John Carroll
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2020

Belgium is ‘European biotech leader’ for 3rd year in a row

Life sciences

Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.

November 22, 2020

J&J, following BMS, pledges $100M to address racism and health inequities

Life sciences

Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.

November 22, 2020

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Send this to a friend